Triomics has secured a $15 million Series A funding round to advance its mission of automating cancer clinical trials matching.
Founded by former MIT biotech researcher Sarim Khan and AI scientist Hrituraj Singh, Triomics aims to address the critical challenge of efficiently matching cancer patients with suitable clinical trials, ultimately improving access to life-saving treatments.
Triomics is a pioneering generative AI startup.
Despite the abundance of clinical trials conducted annually in the United States, only a small fraction of eligible cancer patients enroll in these studies.
Triomics seeks to bridge this gap by leveraging cutting-edge generative AI technology to significantly reduce the time it takes for doctors to identify appropriate trials for their patients.
By automating the process of extracting relevant data from electronic health records (EHR), Triomics’ platform can match patients with trials in minutes rather than hours, streamlining the often cumbersome and time-consuming process.
The inspiration behind Triomics stems from personal experiences, including the founder’s struggles to navigate the complex landscape of clinical trials while seeking treatment options for loved ones.
Recognizing the immense potential of AI to revolutionize cancer care, Khan and Singh embarked on a journey to harness the power of technology to improve patient outcomes and alleviate the burden on oncology medical staff.
Triomics’ flagship product, OncoLLM, is tailored specifically for cancer centers and oncology departments within hospital systems.
By leveraging advanced machine learning algorithms, OncoLLM analyzes patients’ medical records to identify suitable clinical trial matches based on a myriad of criteria, including cancer stage, mutations, and previous treatments.
This innovative approach not only accelerates the patient enrollment process but also empowers healthcare providers with valuable insights to enhance patient care and treatment planning.
The company’s rapid growth and impact are evidenced by its partnerships with six cancer centers and hospitals, with plans to double its customer base by the end of the year.
Backed by leading venture capital firms such as Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, Triomics is poised to expand its reach and further enhance its platform to meet the evolving needs of the healthcare industry.
While Triomics’ primary focus is on streamlining clinical trials matching, its potential applications extend beyond this scope.
The platform’s ability to analyze and extract valuable insights from EHR data has broader implications for improving various aspects of cancer care, including patient visit preparation and regulatory compliance.
Khan envisions Triomics as a versatile tool that empowers healthcare providers with actionable intelligence to deliver personalized and effective care to cancer patients.
Although Triomics faces competition from other AI-driven clinical trial matching startups, its unique approach sets it apart in the market.
By processing large datasets specifically tailored to cancer centers, Triomics demonstrates a commitment to addressing the unique challenges and needs of oncology professionals and patients alike.
Triomics represents a groundbreaking advancement in the intersection of AI and oncology, offering a transformative solution to improve access to clinical trials and enhance patient care.
With its innovative technology and strategic partnerships, Triomics is poised to make a lasting impact on the fight against cancer and pave the way for a future where personalized medicine is accessible to all.
